ArticleBMC pulmonary medicine2026
Role of High flow nasal cannula in managing Type I respiratory failure in patients with neuromuscular disorders.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of acute Type I respiratory failure (RF) in patients with neuromuscular disorders (NMD) and myopathies poses a clinical challenge in the acute care setting. There is a lack of studies which looked into the effectiveness of High flow nasal cannula (HFNC) in acutely ill NMD patients with Type I RF. This single centre, retrospective case-series study was conducted at the RICU of a tertiary care institute in the state of Rajasthan, India, between 1 January 2020 and 31 March 2025 .All patients with a diagnosis of NMD who were admitted in RICU with Type I respiratory failure were sequentially enrolled in the study. Along with demographic and clinical data of patients, arterial blood gas analysis, routine blood and radiological investigations were incorporated in the study. Patient data was traced till the patient was discharged from the hospital or expired. Risk factors for HFNC failure were evaluated. The patient data was analysed using R version 4.5.0. Risk factors found statistically significant on univariate analyses underwent logistic regression .Odds ratio was calculated for those factors which were significant on logistic regression. p value < 0.05 was taken to be significant. In the study period, 42 patients were enrolled, out of whom, 29 (69%) patients could be successfully managed on HFNC, while 13 (31%) patients had HFNC failure. On multiple logistic regression, exacerbation of restrictive lung disease in patients with kyphoscoliosis, serum albumin and Simplified Acute Physiology Score (SAPS) 3 scores were found to be independent risk factors for HFNC failure with Odds ratio (95% CI) of 4.1(2.1-6.1), 6.9(5.2-8.6) and 5.1(3.2-7) respectively. ROX > 4.88 at 12 h had a sensitivity of 80.3% and specificity of 69.23% and an accuracy of 76.2% of predicting HFNC success. This retrospective study shows that HFNC can be an essential adjunct in managing Type I respiratory failure in patients with neuromuscular disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.